The Evaluation of Effectiveness and Safety for New Therapy with Bone Marrow derived Autologous Mesenchymal Stem Cell for Hepatic Failure caused by Alcoholic Liver Cirrhosis
Not Applicable
Completed
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0000266
- Lead Sponsor
- Yonsei University, Wonju Severance Christian Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
(1) Alcoholic liver cirrhosis(child Pugh class B or C, = 7 scores)
, confirmed by clinically or biopsy.
(2) Stop drinking over past 6months.
(3) Patients agree with informed consent
Patients must satisfy all inclusion criteria.
Exclusion Criteria
(1) Patients who did not satisfy inclusion criteria
(2) Hepatocellular carcinoma
(3) Pregnancy or breast feeding
(4) Infective disease(HIV, HBV, HCV..)
(5) Other incurable malignancy
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of liver cirrhosis ;Improvement of portal hypertension
- Secondary Outcome Measures
Name Time Method iver cirrhosis fibrosis grade;Liver mesenchymal cell activity evaluation by immunohistochemistry;Hydroxyproline;Real-Time Polymerase Chain Reaction (TGF-beta, collagen, procollagen, MMP2 or 9);Hepatic vein pressure gradient;Hepatic vein arrival time;Fibroscan;Child-Pugh' score;MELD score;Change of acites